关于草 (Rubi fructus) 在治疗2型糖尿病中的机制的研究基于UPLC-Q-Exactive轨道运行MS,网络药理学和实验验证
Xiaoge Wang1,2, Xueyan Zhang1, Qiyuan Liao1
1Department of Pharmacy, AnHui College of Traditional Chinese Medicine, Wuhu, China.
Phytochemical analysis : PCA
|November 4, 2024
概括
拉斯伯里化合物通过抑制先进的糖化终产品受体 (AGE-RAGE) 信号通路,显示出治疗2型糖尿病的潜力. 在体外研究中证实了拉斯果的存在.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 拉斯伯里富含生物活性化合物,具有潜在的健康益处.
- 2型糖尿病是一种复杂的代谢障碍,具有重大的全球健康影响.
- 了解自然化合物在疾病治疗中的分子机制至关重要.
研究的目的:
- 使用LC-MS.分析大的化学成分.
- 通过网络药理学预测蓝对2型糖尿病的治疗作用.
- 通过体外实验验验证这些效应.
主要方法:
- 液体染色学-质谱学 (LC-MS) 用于化学分析.
- 网络药理学用于目标预测和途径分析 (GO,KEGG).
- 在体外实验中使用HepG2细胞来建模胰岛素耐药性和评估AGE-RAGE通路调节.
主要成果:
- 在拉斯伯里中确定了47种化合物,包括有机酸,黄和.
- 确定了七个活性成分,包括kaempferol和ellagic酸.
- 草治疗降低了RAGE,Akt1和Caspase-3的调节,同时提高了胰岛素抗性HepG2细胞中的p53的调节,这表明AGE-RAGE通路的抑制.
结论:
- 草对2型糖尿病具有潜在的治疗作用.
- 这些效应很可能是通过抑制AGE-RAGE信号通路的介导.
- 为进一步的研究和草在糖尿病管理中的临床应用提供了基础.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
1.9K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
503
相关概念视频
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucose Absorption Into the Small Intestine
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
